Precision medicine has revolutionized the landscape of neurological care, shifting from “one-size-fits-all” approaches to ...

Early and accurate diagnosis is a priority in improving treatment response and in slowing down neurodegeneration and disease progression, regardless of outstanding advancements in therapeutics. Recent ...

As molecular biomarkers go, proteins are possibly the most universally affected by disease state. Protein signatures encompass not only total levels of expression, but predominance of different ...

While the use of precision therapies continues to expand, precision oncology drug development is facing increasing costs and complexity. In today's biomarker-driven landscape, it is more important ...

In a recent review published in the journal Cell, a group of authors established a comprehensive framework for the terminology, characterization, and validation of aging biomarkers to facilitate their ...

In follow-up to the Forum on Neuroscience and Nervous System Disorders' March 2023 workshop on Multimodal Biomarker for Central Nervous System Disorders: Development, Integration and Clinical Utility, ...

GENT, Belgium & FREMONT, Calif.--(BUSINESS WIRE)--ADx NeuroSciences, a wholly owned subsidiary of Fujirebio and a leader in neurodegenerative disease biomarker development, and Alamar Biosciences, a ...

SAN DIEGO & TOKYO & MALVERN, Pa.--(BUSINESS WIRE)--Fujirebio Holdings Inc., its wholly-owned subsidiary Fujirebio Diagnostics, Inc., and AriBio Co., Ltd. announced the completion of a prospective ...

The Prognostic Lung Fibrosis Consortium (PROLIFIC), a collaborative consortium advancing biomarker tools for pulmonary ...